The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity - PubMed (original) (raw)
The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity
M J Berendt et al. J Exp Med. 1978.
Abstract
It was shown that of four syngeneic, murine tumors investigated, only those that evoked the generation of a state of concomitant anti-tumor immunity were susceptible to endotoxin-induced regression. Moreover, the temporal relationship between the generation of concomitant immunity and the onset of susceptibility to endotoxin-induced regression points to the likely possibility that tumor regression depends on the preceding acquisition of the specifically-sensitized, effector T cells that express concomitant immunity. It is suggested that endotoxin-induced hemorrhagic necrosis which invariably precedes tumor regression serves to create conditions inside the tumor that are conducive to the entry and the functioning of effector T cells. It is also suggested that tumor necrosis factor causes hemorrhagic necrosis rather than tumor regression.
Similar articles
- The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.
Berendt MJ, North RJ, Kirstein DP. Berendt MJ, et al. J Exp Med. 1978 Dec 1;148(6):1550-9. doi: 10.1084/jem.148.6.1550. J Exp Med. 1978. PMID: 309921 Free PMC article. - Modulation of antitumor immunity--immunobiologic approaches.
North RJ, Dye ES, Mills CD, Chandler JP. North RJ, et al. Springer Semin Immunopathol. 1982;5(2):193-220. doi: 10.1007/BF00199796. Springer Semin Immunopathol. 1982. PMID: 6293113 Review. No abstract available. - Studies on host defenses enhanced by endotoxins: a brief review.
Nowotny A, Behling UH. Nowotny A, et al. Klin Wochenschr. 1982 Jul 15;60(14):735-9. doi: 10.1007/BF01716566. Klin Wochenschr. 1982. PMID: 6750227 Review.
Cited by
- A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages.
Richert I, Berchard P, Abbes L, Novikov A, Chettab K, Vandermoeten A, Dumontet C, Karanian M, Kerzerho J, Caroff M, Blay JY, Dutour A. Richert I, et al. Cancers (Basel). 2023 Sep 19;15(18):4635. doi: 10.3390/cancers15184635. Cancers (Basel). 2023. PMID: 37760603 Free PMC article. - A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
Chettab K, Fitzsimmons C, Novikov A, Denis M, Phelip C, Mathé D, Choffour PA, Beaumel S, Fourmaux E, Norca P, Kryza D, Evesque A, Jordheim LP, Perrial E, Matera EL, Caroff M, Kerzerho J, Dumontet C. Chettab K, et al. Front Immunol. 2023 May 8;14:1066402. doi: 10.3389/fimmu.2023.1066402. eCollection 2023. Front Immunol. 2023. PMID: 37223101 Free PMC article. - Diet-gut microbial interactions influence cancer immunotherapy.
Wang X, Geng S. Wang X, et al. Front Oncol. 2023 Mar 24;13:1138362. doi: 10.3389/fonc.2023.1138362. eCollection 2023. Front Oncol. 2023. PMID: 37035188 Free PMC article. Review. - Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.
Brown M. Brown M. Cancer Treat Res. 2022;183:91-129. doi: 10.1007/978-3-030-96376-7_3. Cancer Treat Res. 2022. PMID: 35551657 - Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen.
Probst P, Kopp J, Oxenius A, Colombo MP, Ritz D, Fugmann T, Neri D. Probst P, et al. Cancer Res. 2017 Jul 1;77(13):3644-3654. doi: 10.1158/0008-5472.CAN-16-2946. Epub 2017 May 8. Cancer Res. 2017. PMID: 28484076 Free PMC article.
References
- J Exp Med. 1977 Feb 1;145(2):275-92 - PubMed
- J Reticuloendothel Soc. 1978 Apr;23(4):307-19 - PubMed
- J Natl Cancer Inst. 1977 Nov;59(5):1519-22 - PubMed
- Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 - PubMed
- Science. 1977 Aug 26;197(4306):893-5 - PubMed